SolaranRx Inc.
Theranostic for metastatic melanoma
This article was originally published in Start Up
Executive Summary
SolaranRx Inc. is jumping on the theranostics bandwagon by tackling the deadly skin cancer melanoma, which for advanced cases has a staggering survival rate of only six months and a one-year mortality of 75%. The company’s lead compound, SRX-1177, is a novel peptide linked to a radioisotope that can preferentially attach to melanocortin-1, a unique receptor overexpressed on melanoma cells.
You may also be interested in...
Vagisil Marketer Combe Enters Personal Lubricant Market With BioFilm Acquisition
Vagisil and BioFilm’s Astroglide “demonstrate very high levels of brand awareness, brand loyalty, and repeat purchase, and continue to attract new and younger consumers into the category,” firms say.
US Health And Wellness Launches: Perrigo, Lightbody, Nature’s Bounty, PLT, Healthycell, More
Nicotine mint lozenge approval for Perrigo; Lightbody for digital vision health; PLT has broad-spectrum immune health ingredient; Souvenaid for stronger synapses; Kinesiology tape for cellular oxygenation; Healthycell joint health and mobility gel; Nature’s Bounty Optimal Solutions hair, metabolism supplements; and Perricone extends vitamin c ester line.
US Dietary Ingredient ‘Preclusion’ Swings On Information Closed To Supplement Industry – CRN
Trade group contends FDA’s misuse of regulation prohibiting any substance studied or approved as a drug in US from being used as dietary ingredients undermines innovation in supplement industry and is detrimental to consumer choice and health.